Johannes H Schulte
Overview
Explore the profile of Johannes H Schulte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
164
Citations
5603
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Thole L, Toth L, Pross V, Siegle J, Stahl C, Hermsdorf G, et al.
Front Immunol
. 2023 Nov;
14:1239519.
PMID: 37942315
Stem cell transplant recipients (SCTR) are imperiled to increased risks after SARS-CoV2 infection, supporting the need for effective vaccination strategies for this vulnerable group. With respect to pediatric patients, data...
22.
Rodriguez-Fos E, Planas-Felix M, Burkert M, Puiggros M, Toedling J, Thiessen N, et al.
Cell Genom
. 2023 Oct;
3(10):100402.
PMID: 37868040
Neuroblastoma is a pediatric solid tumor characterized by strong clinical heterogeneity. Although clinical risk-defining genomic alterations exist in neuroblastomas, the mutational processes involved in their generation remain largely unclear. By...
23.
Fuchs S, Danssmann C, Klironomos F, Winkler A, Fallmann J, Kruetzfeldt L, et al.
Nat Commun
. 2023 Jul;
14(1):3936.
PMID: 37402719
Circular RNAs (circRNAs) are a regulatory RNA class. While cancer-driving functions have been identified for single circRNAs, how they modulate gene expression in cancer is not well understood. We investigate...
24.
Hagemann S, Misiak D, Bell J, Fuchs T, Lederer M, Bley N, et al.
Mol Cancer
. 2023 May;
22(1):88.
PMID: 37246217
Background: Neuroblastoma is the most common solid tumor in infants accounting for approximately 15% of all cancer-related deaths. Over 50% of high-risk neuroblastoma relapse, emphasizing the need of novel drug...
25.
Chamorro Gonzalez R, Conrad T, Stober M, Xu R, Giurgiu M, Rodriguez-Fos E, et al.
Nat Genet
. 2023 May;
55(5):880-890.
PMID: 37142849
Extrachromosomal DNAs (ecDNAs) are common in cancer, but many questions about their origin, structural dynamics and impact on intratumor heterogeneity are still unresolved. Here we describe single-cell extrachromosomal circular DNA...
26.
Ludwig M, Basti A, Yalcin M, Schulte J, Relogio A
BMC Pediatr
. 2023 Mar;
23(1):105.
PMID: 36870963
Background: In many organisms, including humans, the timing of cellular processes is regulated by the circadian clock. At the molecular level the core-clock consists of transcriptional-translational-feedback loops including several genes...
27.
Flaadt T, Ladenstein R, Ebinger M, Lode H, Arnardottir H, Poetschger U, et al.
J Clin Oncol
. 2023 Feb;
41(17):3135-3148.
PMID: 36854071
Purpose: Patients with relapsed high-risk neuroblastoma (rHR-NB) have a poor prognosis. We hypothesized that graft-versus-neuroblastoma effects could be elicited by transplantation of haploidentical stem cells (haplo-SCT) exploiting cytotoxic functions of...
28.
Rosswog C, Fassunke J, Ernst A, Schomig-Markiefka B, Merkelbach-Bruse S, Bartenhagen C, et al.
Br J Cancer
. 2023 Feb;
128(8):1559-1571.
PMID: 36807339
Background: Genomic alterations of the anaplastic lymphoma kinase gene (ALK) occur recurrently in neuroblastoma, a pediatric malignancy of the sympathetic nervous system. However, information on their development over time has...
29.
Heinz A, Calkoen F, Derbich A, Miltner L, Seitz C, Doering M, et al.
Haematologica
. 2023 Feb;
108(8):2080-2090.
PMID: 36794500
Therapy-resistant viral reactivations contribute significantly to mortality after hematopoietic stem cell transplantation. Adoptive cellular therapy with virus-specific T cells (VST) has shown efficacy in various single-center trials. However, the scalability...
30.
Ivasko S, Anders K, Grunewald L, Launspach M, Klaus A, Schwiebert S, et al.
Front Immunol
. 2023 Jan;
13:1023206.
PMID: 36700232
Introduction: Despite advances in treating high-risk neuroblastoma, 50-60% of patients still suffer relapse, necessitating new treatment options. Bispecific trifunctional antibodies (trAbs) are a promising new class of immunotherapy. TrAbs are...